A phase 2 nonrandomized clinical trial explored whether breast surgery could be safely eliminated for women with ERBB2-positive or triple-negative invasive breast cancer who achieved a pathologic complete...
A randomized trial in breast cancer survivors found that just one session of resistance or high-intensity interval training significantly elevated circulating anti-cancer myokines and reduced the growth of...
The phase 3 SERENA-6 trial evaluated whether replacing an aromatase inhibitor with camizestrant while continuing a CDK4/6 inhibitor in patients with ER-positive, HER2-negative advanced breast cancer and...
In a large multicenter randomized trial, intrapartum oral sildenafil citrate did not reduce adverse perinatal outcomes related to fetal hypoxia compared with placebo.
In women with dense breast tissue and a negative screening mammogram, abbreviated MRI and contrast-enhanced mammography tripled the detection rate of invasive breast cancer compared with automated breast...
A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The 2025 American Society of Clinical Oncology guideline update redefines the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. Building on evidence from major trials, the update...
The latest OVATION-2 trial update, presented at the American Society of Clinical Oncology 2025 annual meeting, shows that adding intraperitoneal IMNN-001 to standard neoadjuvant chemotherapy improved both...
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A retrospective analysis from Memorial Sloan Kettering links higher patient-reported pain to increased emergency department utilization among individuals newly diagnosed with ovarian cancer. This study was...
